Particularly, various cancers expressing a high level of αVβ8 are not usually associated with high programmed cell death ligand 1 (PD-L1) expression, suggesting anti-αVβ8 is a potential immunotherapeutic agent working independently of the PD-1/PD-L1 pathway. The gene discussed is CD274; the disease is cancer.